Home
Charts
Search
Watchlist
Products
All IPOs
₹43 - 43
Goldline Pharmaceutical Ltd
PharmaceuticalsIPOSME
₹43 - 43
We are engaged in the business of marketing pharmaceutical products under the brand name "Goldline." Our product portfolio is organized into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The pharmaceutical products marketed under the "Goldline" brand are not manufactured by our Company. Instead, we enter into contractual arrangements with third-party manufacturers, who produce the products based on our market research, demand analysis, and specifications. These contractual arrangements ensure that all products meet the requisite quality standards and regulatory norms.
Lot3,000Min Invest₹2,58,000Face Value₹10Issue Size₹12 CrFresh Issue₹12 CrListing Price₹60CMP₹30
Timeline
12 May
Bidding opens
14 May
Bidding closes
15 May
Allotment
18 May
Refund & demat credit
19 May
Listing
Subscription
Subscription opens once dates are announced
Reports
Offer Details
Terms
Issue Size₹12 Cr0.27 Cr shares
Fresh Issue₹12 Cr
Face Value₹10
Lot Size3,000 shares
ReservationQIB 49.65% · NII 15.22% · RETAIL 35.13%
Application Sizes
Retail₹2,58,0001-1 lots
sNII₹2,58,000from 2 lots
bNII₹10,32,000from 8 lots
Managers & Registrar
Lead ManagerCumulative Capital Private Limited
RegistrarBigshare Services Pvt Ltd
Ownership & Proceeds
Shareholding
CategoryPre IPOPost IPOPromoter Group79.7%57.3%Public20.3%42.7%
Objects of the Issue
- Repayment of all or a portion of certain outstanding borrowings availed by its company
- General Corporate Purpose
Anchor Book
Bid Date11-May-2026Shares7,32,000Amount₹3 Cr30-day lock-in13-Jun-202690-day lock-in12-Aug-2026
Financials
Profit & Loss
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| RevenueCr | 20 | 24 | 28 | 31 |
| Operating ProfitCr | 2 | 4 | 6 | 7 |
| OPM% | 11.1 | 18.3 | 20.8 | 22.3 |
| PBTCr | 0 | 3 | 4 | 5 |
| PATCr | 0 | 2 | 3 | 4 |
| EPS | 0 | 3 | 4 | 6 |
Balance Sheet
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Equity CapitalCr | 2 | 2 | 7 | 7 |
| ReservesCr | 2 | 4 | 2 | 6 |
| BorrowingsCr | 11 | 11 | 11 | 9 |
| Fixed AssetsCr | - | - | - | 3 |
| Total AssetsCr | 19 | 23 | 26 | 29 |
Cash Flow
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Operating Cash FlowCr | 2 | 3 | 3 | 3 |
| Investing Cash FlowCr | -1 | -1 | 0 | 0 |
| Financing Cash FlowCr | -1 | -1 | -3 | -3 |
| Net Cash FlowCr | 0 | 1 | 0 | -1 |
Strengths & Risks
Strengths · as stated in the DRHP
- Experienced promoters and management team with industry knowledge and a track record.
- Asset-light business model and competitive products.
- Scalable Business Model.
- Wide and diverse range of product offerings.
- Strong Supplier and Vendor Relationships.
- Established Distribution Network.
Strategies · as stated in the DRHP
- Operational Efficiency.
- Product Portfolio Expansion.
- Customer Base Expansion.
- Brand Visibility.
- Customer Satisfaction.
- R&D Investment.
Risks · as stated in the DRHP
- Its rely entirely on third-party contract manufacturers for the manufacturing of the company pharmaceutical products, and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements could adversely affect its business, results of operations and financial condition.
- The Company has experienced delays in filing e-forms with the Registrar of Companies (RoC) in the past, resulting in the payment of late fees. Further, there have also been instances of erroneous filings made by the Company, in the past. While no regulatory actions or penalties has been imposed to date except below mentioned, there is no assurance that such actions will not be levied in the future. The Company cannot guarantee that similar delays will not occur in the future, and if regulatory authorities impose penalties or take punitive actions against the Company or its directors/officers, it could negatively affect the Company's business and financial condition.
- The company commercial success is largely dependent upon its ability to analyses the market of new pharmaceutical products, failure of which may has an adverse impact on its revenue and profitability.
- There has been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay in payment of statutory due in future by the Company, the Regulatory Authorities may impose monetary penalties on it or take certain punitive actions against the Company in relation to the same which may has adverse impact on its business, financial condition and results of operations.
- Its depend on the company distributors for a significant portion of its revenue, and any decrease in revenues or sales from any one of the company key intermediaries may adversely affect its business and results of operations. the Company has a distribution network of 8 distributors and is dependent on these distributors for a significant portion of its revenue. If the company unable to maintain its relationship with such customers or if there is a reduction in their demand for the company products, its business, results of operations and financial condition will be materially and adversely affected.
- There are outstanding mitigations involving the Company, Promoters, Directors, Key Managerial Personnel, Senior Management and Group Companies, if determined adversely, may adversely affect its business and financial condition.